Morgan Stanley’s Lexaria Bioscience LEXX Stock Holding History

Morgan Stanley’s Portfolio LEXX Stock Details LEXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Hold	0	–	–	–	8385
2026 Q1	–	Hold	0	–	–	–	8261
2025 Q4	–	Hold	0	–	–	–	8176
2025 Q1	–	Sell	-1,349	Closed	-$42.5K	–	8167
2024 Q4	$42.5K	Sell	1,349 -183	-12%	-$6.76K	﹤0.01%	6341
2024 Q3	$70.1K	Hold	1,532	–	–	﹤0.01%	6122
2024 Q2	$63.9K	Sell	1,532 -25	-2%	-$1.13K	﹤0.01%	6103
2024 Q1	$84.8K	Buy	+1,557	New	+$59.5K	﹤0.01%	6056
2022 Q1	–	Hold	0	–	–	–	8044
2021 Q4	–	Sell	-67	Closed	-$5.72K	–	8042
2021 Q3	$6K	Buy	+67	New	+$6.43K	﹤0.01%	7450

Other funds holding LEXX

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley's LEXX Position: Q2 2026 in Review

Morgan Stanley held its Lexaria Bioscience (LEXX) position steady in Q2 2026 at 0 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #8385.

Morgan Stanley first reported a position in LEXX in Q3 2021 and has held it in 5 quarters since. The position peaked at $84.8K in Q1 2024. 29 funds tracked by Wall St. Rank hold LEXX as of Q2 2026.

Morgan Stanley held 0 shares of Lexaria Bioscience worth $2 as of Q2 2026.
Morgan Stanley left its Lexaria Bioscience share count unchanged in Q2 2026.
Lexaria Bioscience made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8385 holding.
Morgan Stanley first reported a position in Lexaria Bioscience in Q3 2021 and has held it in 5 quarters since.
Morgan Stanley's Lexaria Bioscience position peaked at $84.8K in Q1 2024.
29 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.